Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer

Castrate-resistant prostate cancer (CRPC) is challenging to treat with the androgen receptor (AR), the main target and key focus of resistance. Understanding the mechanisms of AR interaction with co-regulators will identify new therapeutic targets to overcome AR resistance mechanisms. We previously...

Full description

Bibliographic Details
Main Authors: R. William Watson, Haleema Azam, Claudia Aura, Niamh Russell, Janet McCormack, Eva Corey, Colm Morrissey, John Crown, William M Gallagher, Maria Prencipe
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
enzalutamide
prostate cancer
serum response factor
androgen receptor
Online Access:https://www.mdpi.com/2072-6694/12/12/3540

Internet

https://www.mdpi.com/2072-6694/12/12/3540

Similar Items